Grown Rogue International (GRUSF) EBIT Margin (2009 - 2026)
Grown Rogue International's (GRUSF) quarterly EBIT Margin came in at 1.09% in Q1 2026, up 1101.0% year-on-year from 0.09% in Q1 2025, and up 112.52% quarter-over-quarter from 8.7% in Q4 2025.
Grown Rogue International (GRUSF) EBIT Margin (2009 - 2026) Analysis & Trends
Grown Rogue International's EBIT Margin history runs 16 years deep, the most recent figure standing at 1.09% for Q1 2026.
- On a quarterly basis, EBIT Margin rose 1101.0% year-over-year to 1.09% in Q1 2026; TTM through Mar 2026 was 15653232.31%, a 1565323195.0% increase from a year earlier, with the FY2025 full-year figure at 1.83%, down 206.0% from the prior year.
- EBIT Margin improved to 1.09% in Q1 2026 per GRUSF's latest filing, from 8.7% in the prior quarter.
- Across five years, EBIT Margin topped out at 14.28% in Q1 2023 and bottomed at 15700815.16% in Q2 2025.
- The 5-year median for EBIT Margin is 7.38% (2023), against an average of 1046715.14%.
- Across the five-year window, EBIT Margin surged 10694 bps in 2022 and slumped 1570081681 bps in 2025, its largest moves.
- Year by year, EBIT Margin stood at 13.04% in 2022, then declined by 10 bps to 11.71% in 2023, then sank by 98 bps to 0.23% in 2024, then plunged by 3960 bps to 8.7% in 2025, then jumped by 113 bps to 1.09% in 2026.
- Per Business Quant, the three latest GRUSF EBIT Margin figures stand at 1.09% (Q1 2026), 8.7% (Q4 2025), and 6.83% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | 1.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.09% |
| Dec 31, 2025 | -8.70% |
| Sep 30, 2025 | 6.83% |
| Jun 30, 2025 | -15,700,815.16% |
| Mar 31, 2025 | -9.92% |
| Dec 31, 2024 | 0.23% |
| Sep 30, 2024 | 13.97% |
| Jun 30, 2024 | 1.65% |
| Mar 31, 2024 | 13.93% |
| Dec 31, 2023 | 11.71% |
| Oct 31, 2023 | 8.75% |
| Jul 31, 2023 | 7.38% |
| Apr 30, 2023 | 13.77% |
| Jan 31, 2023 | 14.28% |
| Jan 31, 2022 | 13.04% |
| Oct 31, 2021 | 40.30% |
| Jul 31, 2021 | 23.62% |
| Apr 30, 2021 | -40.49% |
| Jan 31, 2021 | -93.90% |
| Oct 31, 2020 | -288.33% |